SEC Filing Summary: Heatwurx, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Heatwurx, Inc. on March 24, 2015, covering events occurring on March 17, 2015. The registrant is incorporated in Delaware with principal executive offices in Gardena, California. Note: The request metadata referenced "Processa Pharmaceuticals, Inc.," but the filing text explicitly identifies the registrant as Heatwurx, Inc.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements.
Material Changes
On March 17, 2015, Stephen Garland resigned from his position as a director of the Company. The filing states that there were no disagreements between Mr. Garland and the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the director resignation.
Key Facts for Investor Verification
- Stephen Garland resigned as a director on March 17, 2015.
- The resignation was not due to any known disagreement with the Company.
- The filing contains no financial data or operational updates.
- Verify the current composition of the Board of Directors following this resignation.